Question 1

What is ZENOCUTUZUMAB used for?

Accepted Answer

ZENOCUTUZUMAB (brand name BIZENGRI) is a Other indicated for 1 INDICATIONS AND USAGE BIZENGRI® is a bispecific HER2- and HER3-directed antibody indicated for the treatment of: Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 ( NRG1 ) gene fusion with disease progression on or after prior systemic therapy.* ( 1.1 ) Adults with advanced.

Question 2

How does ZENOCUTUZUMAB work?

Accepted Answer

ZENOCUTUZUMAB works through the following mechanism: 12.1 Mechanism of Action Zenocutuzumab-zbco is a bispecific antibody that binds to the extracellular domains of HER2 and HER3 expressed on the surface of cells, including tumor cells, inhibiting HER2:HER3 dimerization and preventing NRG1 binding to HER3. Zenocutuzumab-zbco decreased cell proliferation and signaling through the phosphoinositide 3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway. In addition, zenocutuzumab-zbco mediates antibody-dependent cellular cytotoxicity (ADCC). Zenocutuzumab-zbco showed antitumor activity in mouse models of NRG1 fusion-positive lung and pancreatic cancers..

Question 3

What are the most common side effects of ZENOCUTUZUMAB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for ZENOCUTUZUMAB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is ZENOCUTUZUMAB the same as BIZENGRI?

Accepted Answer

BIZENGRI is a brand name for ZENOCUTUZUMAB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

ZENOCUTUZUMAB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations